Saol Therapeutics News

ROSWELL, Ga, DUBLIN and HAMILTON, Bermuda, February 13, 2023 – Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, is proud to announce it has received the 2023 Innovation Award from the Center for Global Health Innovation’s (CGHI) Office of Life Sciences and Digital Health. CGHI - formerly known as Georgia Bio - is the state’s life science trade association.

The Innovation Award is presented to the “department, institution, company or individuals who are forging new ground by thinking outside traditional paradigms to create some unique technology.”

“We are honored to receive the 2023 Innovation Award from the Center for Global Health Innovation,” stated Saol Therapeutics CEO David Penake. “2022 was a transformational year for our company which has set Saol up for a tremendous future. It’s a wonderful honor for each employee at Saol to know that their hard work and progress in bringing new therapies to patients is being recognized.”

“The life science industry in Georgia is booming and a significant amount of that growth is due to the team at CGHI,” added Penake. “They are doing an unbelievable job driving new investment and growth in this space and to be recognized by a group that we align with and admire is incredibly meaningful to all of us at Saol.”

In 2022, Saol Therapeutics transformed from a global commercial organization to a late-stage development company. In the last 18 months, Saol divested all commercialized assets as well as two development programs, including one of which that was recently approved by the FDA. The proceeds from the transactions have fully funded current research activities for development programs SL-1002 and SL-1009. SIL-1002 is in two separate phase II studies in adult patients, one studying its effect for knee pain associated with osteoarthritis and the other for the treatment of spasticity. SIL-1009 is in a Phase III trial for a rare pediatric mitochondrial disease that recently completed enrollment, and a Phase II trial in glioblastoma. The topline results for all these studies are expected later in 2023.

The award will be presented when CGHI celebrates its 25th annual Golden Helix Awards on Wednesday, March 29th at the Fox Theatre in Atlanta, GA.

To view the press release from CGHI, including a list of all the 2023 honorees, please click here.

About Saol Therapeutics

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations. For more information, visit www.saolrx.com.